BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27442883)

  • 1. African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014.
    Weyer CT; Grewar JD; Burger P; Rossouw E; Lourens C; Joone C; le Grange M; Coetzee P; Venter E; Martin DP; MacLachlan NJ; Guthrie AJ
    Emerg Infect Dis; 2016 Dec; 22(12):2087-2096. PubMed ID: 27442883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals.
    von Teichman BF; Smit TK
    Vaccine; 2008 Sep; 26(39):5014-21. PubMed ID: 18682269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A field investigation of an African horse sickness outbreak in the controlled area of South Africa in 2016.
    Grewar JD; Weyer CT; Venter GJ; van Helden LS; Burger P; Guthrie AJ; Coetzee P; Labuschagne K; Bührmann G; Parker BJ; Thompson PN
    Transbound Emerg Dis; 2019 Mar; 66(2):743-751. PubMed ID: 30449073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine.
    Weyer CT; Grewar JD; Burger P; Joone C; Lourens C; MacLachlan NJ; Guthrie AJ
    Vaccine; 2017 Apr; 35(18):2504-2510. PubMed ID: 28341113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
    Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
    Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.
    Calvo-Pinilla E; Marín-López A; Utrilla-Trigo S; Jiménez-Cabello L; Ortego J
    Curr Opin Virol; 2020 Oct; 44():49-56. PubMed ID: 32659516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of the African horse sickness virus S10 gene.
    Quan M; van Vuuren M; Howell PG; Groenewald D; Guthrie AJ
    J Gen Virol; 2008 May; 89(Pt 5):1159-1168. PubMed ID: 18420793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using a new serotype-specific Polymerase Chain Reaction (PCR) and sequencing to differentiate between field and vaccine-derived African Horse Sickness viruses submitted in 2016/2017.
    van Schalkwyk A; Ferreira ML; Romito M
    J Virol Methods; 2019 Apr; 266():89-94. PubMed ID: 30721715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6.
    von Teichman BF; Dungu B; Smit TK
    Vaccine; 2010 Sep; 28(39):6505-17. PubMed ID: 20638456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
    van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
    Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. African horse sickness in The Gambia: circulation of a live-attenuated vaccine-derived strain.
    Oura CA; Ivens PA; Bachanek-Bankowska K; Bin-Tarif A; Jallow DB; Sailleau C; Maan S; Mertens PC; Batten CA
    Epidemiol Infect; 2012 Mar; 140(3):462-5. PubMed ID: 21733265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a mouse model system, coding assignments and identification of the genome segments controlling virulence of African horse sickness virus serotypes 3 and 8.
    O'Hara RS; Meyer AJ; Burroughs JN; Pullen L; Martin LA; Mertens PP
    Arch Virol Suppl; 1998; 14():259-79. PubMed ID: 9785512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
    Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
    Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African Thoroughbred foals.
    Crafford JE; Lourens CW; Gardner IA; Maclachlan NJ; Guthrie AJ
    Equine Vet J; 2013 Sep; 45(5):604-7. PubMed ID: 23294121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic applications of molecular and serological assays for bluetongue and African horse sickness.
    Mayo CE; Weyer CT; Carpenter MJ; Reed KJ; Rodgers CP; Lovett KM; Guthrie AJ; Mullens BA; Barker CM; Reisen WK; MacLachlan NJ
    Rev Sci Tech; 2021 Jun; 40(1):91-104. PubMed ID: 34140738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.
    van Rijn PA; Maris-Veldhuis MA; Grobler M; Wright IM; Erasmus BJ; Maartens LH; Potgieter CA
    Vaccine; 2020 Oct; 38(45):7108-7117. PubMed ID: 32921506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control and eradication of African horse sickness with vaccine.
    Sánchez-Vizcaíno JM
    Dev Biol (Basel); 2004; 119():255-8. PubMed ID: 15742636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.